ERBB2 and neoplasm: The protein biomarkers assess hormone response (PR, FOXA1), aggressiveness (HER2), proliferation (Ki-67), cell cycle regulation (p16/CDKN2A) and stress response (COX2, SIAH2), while the clinicopathologic features include age, tumor size, margin status and palpability [73] (Table 4).